Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $18.15 in the prior trading day, 10x Genomics Inc (NASDAQ: TXG) closed at $17.77, down -2.09%. In other words, the price has decreased by -$2.09 from its previous closing price. On the day, 1.9 million shares were traded. TXG stock price reached its highest trading level at $18.2 during the session, while it also had its lowest trading level at $17.39.
Ratios:
Our goal is to gain a better understanding of TXG by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.66 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 30.79. For the most recent quarter (mrq), Quick Ratio is recorded 4.06 and its Current Ratio is at 4.48. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
On September 11, 2025, Piper Sandler started tracking the stock assigning a Neutral rating and target price of $15.
Leerink Partners Downgraded its Outperform to Market Perform on February 13, 2025, whereas the target price for the stock was revised from $25 to $12.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 24 ’25 when Taich Adam sold 11,888 shares for $19.00 per share. The transaction valued at 225,852 led to the insider holds 297,385 shares of the business.
Hindson Benjamin J. sold 8,283 shares of TXG for $157,363 on Nov 24 ’25. The insider now owns 432,605 shares after completing the transaction at $19.00 per share. On Nov 24 ’25, another insider, Saxonov Serge, who serves as the Chief Executive Officer of the company, sold 13,261 shares for $19.00 each. As a result, the insider received 251,936 and left with 1,021,556 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TXG now has a Market Capitalization of 2248847616 and an Enterprise Value of 1853748736. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.50 while its Price-to-Book (P/B) ratio in mrq is 2.86. Its current Enterprise Value per Revenue stands at 2.888 whereas that against EBITDA is -19.013.
Stock Price History:
The Beta on a monthly basis for TXG is 2.17, which has changed by 0.10030961 over the last 52 weeks, in comparison to a change of 0.13506866 over the same period for the S&P500. Over the past 52 weeks, TXG has reached a high of $20.34, while it has fallen to a 52-week low of $6.78. The 50-Day Moving Average of the stock is 23.05%, while the 200-Day Moving Average is calculated to be 50.01%.
Shares Statistics:
The stock has traded on average 2.84M shares per day over the past 3-months and 2898290 shares per day over the last 10 days, according to various share statistics. A total of 116.46M shares are outstanding, with a floating share count of 111.97M. Insiders hold about 11.52% of the company’s shares, while institutions hold 96.81% stake in the company. Shares short for TXG as of 1763078400 were 15501651 with a Short Ratio of 5.45, compared to 1760486400 on 12546318. Therefore, it implies a Short% of Shares Outstanding of 15501651 and a Short% of Float of 19.469998999999998.
